Free Trial
NASDAQ:RNXT

RenovoRx Q2 2024 Earnings Report

RenovoRx logo
$1.04 +0.01 (+0.97%)
As of 02:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RenovoRx EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

RenovoRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

RenovoRx Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

RenovoRx's Q1 2025 earnings is scheduled for Thursday, May 15, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

RenovoRx Earnings Headlines

RenovoRx (RNXT) Projected to Post Earnings on Friday
All Signs Point To Collapse - 401(k)s/IRAs /Are Doomed
Retiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road Ahead
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT), a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

View RenovoRx Profile

More Earnings Resources from MarketBeat